Lilly Australia
Lilly Australia is the Australian subsidiary of Eli Lilly and Company, developing and supplying patented prescription medicines across diabetes, obesity, oncology, neurology, and immunology, distributed through pharmacies, healthcare providers, and the LillyDirect platform.
- Company typePrivate
- Founded1876
- HeadquartersSydney, Australia
- Headcount251–500
- GTM typeB2C
- OfferingHardware or Manufacturing
What Lilly Australia does
Lilly Australia is the Australian operating subsidiary of Eli Lilly and Company (NYSE: LLY), a US-headquartered multinational pharmaceutical company founded in 1876. The Australian entity operates from Sydney with 251-500 employees and markets patented prescription medicines across eight therapeutic areas: arthritis, cancer, dermatology, diabetes, migraine, obesity, sleep apnoea, and Alzheimer's disease. Its flagship product in Australia is Mounjaro (tirzepatide) for type 2 diabetes, alongside a broader portfolio of genetic medicine research aimed at developing therapies tailored to individual biology.
The company's revenue model centers on prescription medication sales distributed through Australian pharmacies, healthcare providers, and the LillyDirect direct-to-consumer platform, which connects patients with independent doctors. Pricing is mediated through the Pharmaceutical Benefits Scheme (PBS) for subsidized access or private prescription channels. In 2026, Lilly Australia withdrew Mounjaro from the PBS listing process due to a pricing dispute with the federal government, an event that affected approximately 450,000 Australians with type 2 diabetes. The subsidiary is supported by the parent company's 150-year heritage, 100+ patented medications, and 2 Nobel Prizes for medicine, and engages in cultural partnerships such as Vivid Sydney 2026 for brand awareness.
Lilly Australia firmographics
Firmographics- Name
- Lilly Australia
- Legal name
- Lilly Australia
- Website
- https://lilly.com.au
- Company type
- Private
- Founded year
- 1876
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Lilly Australia is the Australian subsidiary of Eli Lilly and Company, developing and supplying patented prescription medicines across diabetes, obesity, oncology, neurology, and immunology, distributed through pharmacies, healthcare providers, and the LillyDirect platform.
- Ownership category
- akta.pro rank
Lilly Australia industry classification
Industry- Product category
- Prescription Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Lilly Australia is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Markets served
Lilly Australia business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Revenue generated from patented medications sold to patients and healthcare providers through pharmacies and medical channels
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing through healthcare system |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Lilly Australia product offering
Product offeringCore offering
Lilly Australia develops, registers, and supplies patented prescription medicines across multiple therapeutic areas including diabetes, obesity, arthritis, cancer, dermatology, migraine, sleep apnoea, and Alzheimer's disease. The company also operates the LillyDirect platform connecting patients with independent doctors, conducts patient recruitment for clinical trials, and runs affordability/access programs to support treatment uptake in Australia.
Product overview
Lilly Australia is a pharmaceutical company that develops and manufactures medicines. The company operates across multiple therapeutic areas including Arthritis, Cancer, Dermatology, Diabetes, Migraine, Obesity, Sleep apnoea, and Alzheimer's disease. Their product portfolio centers on patented medications, with key offerings including Mounjaro (tirzepatide) for diabetes treatment. The company provides patient-facing services such as finding care through independent doctors, joining clinical trials, and accessing medicines through affordability programs. They also conduct research in genetic medicines.
Differentiator
Problem solved
Functional benefit
Brands
- LillyDirect: A direct-to-consumer healthcare service connecting patients with independent doctors who understand their conditions.
Products and services
- Mounjaro (tirzepatide) A patented prescription medication (tirzepatide) for the treatment of type 2 diabetes in adult patients. Sold in Australia through physician prescriptions, the Pharmaceutical Benefits Scheme (PBS), and private prescription channels.
- LillyDirect Platform
- Clinical Trial Participation Program A program offering Australian patients the opportunity to enroll in clinical trials for Lilly's investigational medicines across therapeutic areas such as arthritis, cancer, dermatology, diabetes, migraine, obesity, sleep apnoea, and Alzheimer's disease. Supports R&D pipeline progression.
Companies that use Lilly Australia
Customer profileSegments8 records
Ideal customer profiles3 records
Lilly Australia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Lilly Australia partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Vivid SydneyminorLilly Australia was a key partner for Vivid Sydney 2026, the world's largest multidisciplinary arts festival. The partnership was part of brand awareness and community engagement initiatives in Australia.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Lilly Australia competitors and assessment
Company assessmentDirect peers
- AbbVie Australia: Australian subsidiary of AbbVie, with a heavy focus on immunology (Humira/Skyrizi/Rinvoq) and oncology. Comparable to Lilly Australia in specialty-pharma distribution, immunology presence, and PBS-listed product portfolio.
- Sanofi Australia: Australian subsidiary of Sanofi, focused on specialty care, immunology (Dupixent), diabetes, and rare disease. Comparable to Lilly Australia in operating model and therapeutic area overlap, particularly in immunology and diabetes.
- Pfizer Australia: Australian subsidiary of Pfizer, a large multinational pharmaceutical company. Comparable to Lilly Australia in operating model — multi-therapeutic-area branded pharma distribution, PBS participation, and direct subsidiary structure of a US parent.
- Roche Australia: Australian subsidiary of Roche, with a strong oncology and specialty-care portfolio. Comparable to Lilly Australia in the Australian branded-pharma distribution model, hospital/specialty channel access, and participation in PBS listings across multiple therapeutic areas.
- Novo Nordisk Australia: Australian subsidiary of Novo Nordisk, the direct global competitor in the GLP-1/incretin class with Ozempic and Wegovy. Comparable to Lilly Australia as a major-country pharmaceutical subsidiary focused heavily on diabetes and obesity, competing head-to-head on Mounjaro.
- Merck Sharp & Dohme (MSD) Australia: Australian subsidiary of Merck & Co., with a major oncology (Keytruda) and vaccines portfolio. Comparable to Lilly Australia as a large multinational pharma subsidiary distributing PBS-listed branded medicines across multiple therapeutic areas.
- AstraZeneca Australia: Australian subsidiary of AstraZeneca with a broad oncology, cardiovascular, and respiratory portfolio. Comparable to Lilly Australia as a multinational pharma subsidiary operating across multiple therapeutic areas with PBS-listed products in Australia.
- GSK Australia: Australian subsidiary of GSK, operating across specialty medicines, vaccines, and HIV. Comparable to Lilly Australia in the multi-therapeutic branded pharma distribution model and PBS participation.
- Johnson & Johnson Innovative Medicine Australia (Janssen): Australian pharmaceutical arm of J&J, with a strong oncology, immunology, and neuroscience portfolio. Comparable to Lilly Australia in the multi-therapeutic branded pharma model, hospital/specialty channel presence, and PBS participation.
- Bayer Australia: Australian subsidiary of Bayer, with a pharmaceutical portfolio spanning women's health, cardiology, and specialty care. Comparable to Lilly Australia as a multinational pharma subsidiary with PBS-listed products and multi-therapeutic-area coverage.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Lilly Australia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lilly Australia leadership team
Management profileNumber of profiles
Lilly Australia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lilly Australia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lilly Australia
What does Lilly Australia do?
Lilly Australia develops, registers, and supplies patented prescription medicines across multiple therapeutic areas including diabetes, obesity, arthritis, cancer, dermatology, migraine, sleep apnoea, and Alzheimer's disease. The company also operates the LillyDirect platform connecting patients with independent doctors, conducts patient recruitment for clinical trials, and runs affordability/access programs to support treatment uptake in Australia.
Is Lilly Australia a public or private company?
Lilly Australia is a private company. It is classified as corporate owned and is currently operating.
When was Lilly Australia founded?
Lilly Australia was founded in 1876. It employs 251 to 500 people.
Where is Lilly Australia based?
Lilly Australia is headquartered in Sydney, Australia, in the Oceania region.
How does Lilly Australia make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Lilly Australia's main competitors?
Direct peers on record are AbbVie Australia, Sanofi Australia, Pfizer Australia, Roche Australia, Novo Nordisk Australia, Merck Sharp & Dohme (MSD) Australia, AstraZeneca Australia, GSK Australia, Johnson & Johnson Innovative Medicine Australia (Janssen) and Bayer Australia.
Does Lilly Australia have an API?
No public API is recorded for Lilly Australia.
What industry is Lilly Australia in?
Lilly Australia's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.